Change in disease activity, radiographic damage, physical function and quality of life between baseline and 12 months
| GUEPARD (N=65) | ESPOIR (N=130) | p Value | |
|---|---|---|---|
| DAS28 | −3.12 (−3.56 to −2.67) | −2.65 (−2.94 to −2.37) | 0.12 |
| Tender joint count (range 0–28) | −10.1 (−12.4 to −7.9) | −9.1 (−10.6 to −7.6) | 0.51 |
| Swollen joint count (range 0–28) | −7.7 (−9.5 to −5.9) | −8.0 (−9.1 to −6.8) | 0.84 |
| Pain score (range 0–100 mm VAS) | −44.8 (−52.6 to −37.0) | −24.2 (−29.2 to −19.1) | <0.001 |
| Patient global assessment (range 0–100 mm VAS) | −46.6 (−55.3 to −37.9) | −32.3 (−37.9 to −26.7) | 0.02 |
| Physician global assessment (range 0–100 mm VAS) | −49.1 (−57.1 to −41.1) | −36.0 (−41.1 to −30.8) | 0.02 |
| ESR, mm/h | −19.5 (−26.7 to −12.3) | −20.6 (−25.3 to −16.0) | 0.82 |
| CRP (mg/l) | −24.8 (−35.1 to −14.5) | −18.8 (−25.5 to −12.1) | 0.39 |
| HAQ score (range 0–3) | −0.94 (−1.15 to −0.72) | −0.68 (−0.81 to −0.55) | 0.07 |
| Fatigue (range 0–100 mm VAS) | −37.1 (−46.0 to −28.3) | −12.2 (−17.9 to −6.5) | <0.0001 |
| Physical component summaries of SF-36 (range 0–100) | 9.66 (6.73 to 12.59) | 8.75 (6.97 to 10.53) | 0.64 |
| Mental component summaries of SF-36 (range 0–100) | 9.26 (5.38 to 13.14) | 3.92 (1.56 to 6.27) | 0.04 |
| Erosion score, 0–280 scale | 0.4 (−0.6 to 1.3) | 1.3 (0.8 to 1.9) | 0.12 |
| JSN score, 0–168 scale | 0.6 (0.2 to 1.0) | 0.2 (0.0 to 0.4) | 0.13 |
| Total SHS, 0–448 scale | 0.9 (−0.2 to 2.1) | 1.5 (0.8 to 2.3) | 0.46 |
Mean change (95% CI).
CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; JSN, joint-space narrowing; SHS, modified Sharp/van der Heijde score; VAS, visual analogue scale.